NeuImmune, Inc. is an early-stage biotechnology company

… founded by leading scientists in the field of glyco- and cell-engineering from the University of Maryland, University of California, San Diego, and the Technical University of Denmark.

Our Vision

Our vision, through the engineering of precision biologics, is to position NeuImmune as the leading glycoprotein therapeutics company focused on addressing enzyme replacement therapies associated with unmet orphan disease conditions, starting with lysosomal storage disorders.

Platform Technologies

geCHO BioDesign Platform

NeuImmune, and its scientific founders, have developed a comprehensive panel of glycoengineered CHO cells (geCHO) that can uniformly produce diverse human-like glycoforms of a therapeutic protein and/or vaccine antigen. In addition, the company has developed comprehensive AI platforms to facilitate identification of optimal glycoforms associated with desired functional activity and conditions for bioproduction optimization using the panel of geCHO cell lines.

ICAM-1 Targeting Technology

Intercellular adhesion molecule-1 (ICAM-1) is an immunoglobulin-(Ig)-like transmembrane glycoprotein overexpressed on the endothelial lumen during many pathological states, including lysosomal storage disorders. By combining our geCHO proteins with an ICAM-1-binding peptide, we can enhance cellular delivery and enzymatic activity under conditions that mimic the lysosomal environment to enable highly efficient CNS and visceral organ access via intravenous dosing, reduce dose/frequency, and lower risk for hypersensitivity, and resistance

Our Pipeline

Learn more about our innovative pipeline…